CN102451164B - 一种镇痛药口腔崩解片及其制备方法 - Google Patents
一种镇痛药口腔崩解片及其制备方法 Download PDFInfo
- Publication number
- CN102451164B CN102451164B CN201010523561.1A CN201010523561A CN102451164B CN 102451164 B CN102451164 B CN 102451164B CN 201010523561 A CN201010523561 A CN 201010523561A CN 102451164 B CN102451164 B CN 102451164B
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- disintegrating tablet
- tablet
- analgesic
- untoward reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000214 mouth Anatomy 0.000 title claims abstract description 134
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 64
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000004108 freeze drying Methods 0.000 claims abstract description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 63
- 239000000243 solution Substances 0.000 claims description 60
- 239000008213 purified water Substances 0.000 claims description 46
- 239000004373 Pullulan Substances 0.000 claims description 42
- 229920001218 Pullulan Polymers 0.000 claims description 42
- 235000019423 pullulan Nutrition 0.000 claims description 42
- 239000004471 Glycine Substances 0.000 claims description 38
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 36
- 229930195725 Mannitol Natural products 0.000 claims description 36
- 239000000594 mannitol Substances 0.000 claims description 36
- 235000010355 mannitol Nutrition 0.000 claims description 36
- 229920002307 Dextran Polymers 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 239000004376 Sucralose Substances 0.000 claims description 20
- 230000012447 hatching Effects 0.000 claims description 20
- 235000019408 sucralose Nutrition 0.000 claims description 20
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 20
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 14
- 229960004380 tramadol Drugs 0.000 claims description 14
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 14
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 8
- 206010010774 Constipation Diseases 0.000 claims description 8
- 206010047700 Vomiting Diseases 0.000 claims description 8
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 8
- 229960004998 acesulfame potassium Drugs 0.000 claims description 8
- 239000000619 acesulfame-K Substances 0.000 claims description 8
- 108010011485 Aspartame Proteins 0.000 claims description 6
- 239000000605 aspartame Substances 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- 229960003438 aspartame Drugs 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 18
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 18
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 9
- 229960004126 codeine Drugs 0.000 claims 9
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 9
- 229960005181 morphine Drugs 0.000 claims 9
- 230000003287 optical effect Effects 0.000 claims 9
- 229960002085 oxycodone Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 230000036592 analgesia Effects 0.000 claims 7
- 238000001746 injection moulding Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000010579 first pass effect Methods 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 208000019505 Deglutition disease Diseases 0.000 abstract description 4
- 231100000017 mucous membrane irritation Toxicity 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000008014 freezing Effects 0.000 description 27
- 238000007710 freezing Methods 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 21
- 229960005195 morphine hydrochloride Drugs 0.000 description 21
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 21
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 21
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 20
- 229960004415 codeine phosphate Drugs 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 238000002156 mixing Methods 0.000 description 16
- 229960003107 tramadol hydrochloride Drugs 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 235000006679 Mentha X verticillata Nutrition 0.000 description 10
- 235000002899 Mentha suaveolens Nutrition 0.000 description 10
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 8
- 210000002200 mouth mucosa Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000013019 agitation Methods 0.000 description 7
- 241000220223 Fragaria Species 0.000 description 6
- 235000016623 Fragaria vesca Nutrition 0.000 description 6
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- -1 oral solution Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 5
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 5
- 239000007968 orange flavor Substances 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 241000234671 Ananas Species 0.000 description 4
- 235000007119 Ananas comosus Nutrition 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 229940041984 dextran 1 Drugs 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940119743 dextran 70 Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940095262 codeine phosphate 30 mg Drugs 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | 完全缓解 | 部分缓解 | 轻度缓解 | 无效 | 有效率(%) |
R1组 | 5 | 14 | 6 | 5 | 63.3 |
R2组 | 6 | 14 | 4 | 6 | 66.7 |
R3组 | 7 | 14 | 5 | 4 | 70.0 |
R4组 | 5 | 13 | 6 | 6 | 60.0 |
T1 | 18 | 9 | 3 | 0 | 90.0 |
T2 | 18 | 9 | 3 | 0 | 90.0 |
T3 | 17 | 9 | 4 | 0 | 86.7 |
T4 | 16 | 11 | 3 | 0 | 90.0 |
T5 | 17 | 10 | 3 | 0 | 90.0 |
T6 | 19 | 9 | 2 | 0 | 93.3 |
T7 | 18 | 10 | 2 | 0 | 93.3 |
T8 | 19 | 9 | 2 | 0 | 93.3 |
T9 | 17 | 10 | 2 | 0 | 90.0 |
T10 | 18 | 10 | 2 | 0 | 93.3 |
T11 | 20 | 9 | 1 | 0 | 96.7 |
T12 | 18 | 10 | 2 | 0 | 93.3 |
T13 | 20 | 9 | 1 | 0 | 96.7 |
T14 | 19 | 10 | 1 | 0 | 96.7 |
T15 | 19 | 10 | 1 | 0 | 96.7 |
T16 | 17 | 9 | 4 | 0 | 86.7 |
T17 | 17 | 9 | 4 | 0 | 86.7 |
T18 | 16 | 9 | 5 | 0 | 83.3 |
T19 | 16 | 10 | 4 | 0 | 86.7 |
T20 | 16 | 10 | 4 | 0 | 86.7 |
组别 | 恶心 | 呕吐 | 便秘 | 嗜睡 | 尿滞留 |
R1组 | 33.33%(10人) | 23.33%(7人) | 33.33%(10人) | 6.67%(2人) | 6.67%(2人) |
R2组 | 43.33%(13人) | 23.33%(7人) | 10%(3人) | 10%(3人) | 3.33%(1人) |
R3组 | 30%(9人) | 33.33%(10人) | 33.33%(10人) | 6.67%(2人) | 6.67%(2人) |
R4组 | 26.67%(8人) | 23.33%(7人) | 20%(6人) | 6.67%(2人) | 3.33%(1人) |
T1 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T2 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T3 | 6.67%(2人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T4 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T5 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T6 | 6.67%(2人) | 3.33%(1人) | 0% | 0% | 0% |
T7 | 6.67%(2人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T8 | 6.67%(2人) | 3.33%(1人) | 0% | 0% | 0% |
T9 | 6.67%(2人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T10 | 6.67%(2人) | 3.33%(1人) | 0% | 0% | 0% |
T11 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T12 | 3.33%(1人) | 6.67%(2人) | 3.33%(1人) | 0% | 0% |
T13 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T14 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T15 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T16 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T17 | 3.33%(1人) | 3.33%(1人) | 0% | 0% | 0% |
T18 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T19 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
T20 | 3.33%(1人) | 3.33%(1人) | 3.33%(1人) | 0% | 0% |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010523561.1A CN102451164B (zh) | 2010-10-22 | 2010-10-22 | 一种镇痛药口腔崩解片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010523561.1A CN102451164B (zh) | 2010-10-22 | 2010-10-22 | 一种镇痛药口腔崩解片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102451164A CN102451164A (zh) | 2012-05-16 |
CN102451164B true CN102451164B (zh) | 2015-11-25 |
Family
ID=46035108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010523561.1A Active CN102451164B (zh) | 2010-10-22 | 2010-10-22 | 一种镇痛药口腔崩解片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102451164B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112494450A (zh) * | 2020-12-12 | 2021-03-16 | 海南海神同洲制药有限公司 | 化学药专用口腔崩解片包覆结构及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528273A (zh) * | 2003-10-21 | 2004-09-15 | 宇 周 | 一种镇痛药盐酸曲马多口腔崩解片及其制备方法 |
CN1559388A (zh) * | 2004-02-27 | 2005-01-05 | 中奇制药技术(石家庄)有限公司 | 盐酸曲马多口腔崩解片及制备方法 |
CN1660056A (zh) * | 2004-12-24 | 2005-08-31 | 河南大学 | 盐酸曲马多口腔崩解片剂及其制备方法 |
CN1689649A (zh) * | 2004-04-30 | 2005-11-02 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
CN1915215A (zh) * | 2005-08-17 | 2007-02-21 | 量子高科(北京)研究院有限公司 | 一种口腔崩解制剂 |
-
2010
- 2010-10-22 CN CN201010523561.1A patent/CN102451164B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528273A (zh) * | 2003-10-21 | 2004-09-15 | 宇 周 | 一种镇痛药盐酸曲马多口腔崩解片及其制备方法 |
CN1559388A (zh) * | 2004-02-27 | 2005-01-05 | 中奇制药技术(石家庄)有限公司 | 盐酸曲马多口腔崩解片及制备方法 |
CN1689649A (zh) * | 2004-04-30 | 2005-11-02 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
CN1660056A (zh) * | 2004-12-24 | 2005-08-31 | 河南大学 | 盐酸曲马多口腔崩解片剂及其制备方法 |
CN1915215A (zh) * | 2005-08-17 | 2007-02-21 | 量子高科(北京)研究院有限公司 | 一种口腔崩解制剂 |
Non-Patent Citations (2)
Title |
---|
氨酚曲马多口腔崩解片中有关物质的HPLC测定;张冬梅等;《中国医药工业杂志》;20071231;第38卷(第1期);第36-38页 * |
盐酸曲马多口腔崩解片的研制;陈洪轩等;《中国医院药学杂志》;20080531;第28卷(第9期);第715-718页 * |
Also Published As
Publication number | Publication date |
---|---|
CN102451164A (zh) | 2012-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5756483A (en) | Pharmaceutical compositions for intranasal administration of apomorphine | |
CN101698101B (zh) | 一种治疗阴道炎的药物组合物 | |
WO2009046620A1 (en) | Cycloastragenol monoglucoside, preparation, pharmaceutical composition and application thereof | |
CN102552191B (zh) | 一种5-ht受体激动剂口腔崩解片及其制备方法 | |
CN104000789A (zh) | 一种阿德福韦酯分散片及其制备方法 | |
CN102451164B (zh) | 一种镇痛药口腔崩解片及其制备方法 | |
CN102579376B (zh) | 一种非甾体抗炎药口腔崩解片及其制备方法 | |
CN102451165A (zh) | 罗通定口腔崩解片及其制备方法 | |
CN102552192A (zh) | 一种镇静催眠药口腔崩解片及其制备方法 | |
CN102451169B (zh) | 氯雷他定冻干片及其制备方法 | |
CN102451167A (zh) | 一种h1受体拮抗剂口腔崩解片及其制备方法 | |
CN102525972B (zh) | 一种钙离子拮抗剂口腔崩解片及其制备方法 | |
CN102525970B (zh) | 一种抗痴呆药物口腔崩解片及其制备方法 | |
CN105434382A (zh) | 琥珀酸曲格列汀冻干口腔崩解片 | |
CN102451170B (zh) | 盐酸格拉司琼冻干片及其制备方法 | |
CN101797237A (zh) | 甲磺酸倍他司汀口腔崩解片及其制备方法 | |
CN112618504B (zh) | 含有灯盏细辛提取物和冰片的药物组合物及其制备方法 | |
CN102462685B (zh) | 一种咪达唑仑组合物、其制备方法及用途 | |
CN102302477B (zh) | 一种华蟾酥毒基干粉吸入剂及其制备方法、应用 | |
CN101244049A (zh) | 盐酸克仑特罗双层缓释片及其制备方法 | |
CN102525971A (zh) | 一种促胃肠动力药口腔崩解片及其制备方法 | |
CN104188930B (zh) | 一种阿西美辛三层控释片及其制备方法 | |
CN102579375A (zh) | 一种降脂药物口腔崩解片及其制备方法 | |
CN101627971A (zh) | 纳米结晶米格列奈钙口腔崩解片及其制备方法 | |
CN102451166A (zh) | 一种司琼类药物口腔崩解片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: Wang Libin Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 102200 Changping District Road, Beijing, No. 8, No. 11 building Applicant after: Quantum Hi-Tech Research Institute (Beijing) Co., Ltd. Address before: 065201 Yingbin Road, Yanjiao economic and Technological Development Zone, Langfang, Hebei Applicant before: Quantum Hi-Tech Research Institute (Beijing) Co., Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191018 Address after: Room 503, building 11, yard 8, Heying Road, east industrial base, science and Technology Park, Changping District, Beijing 102200 (Changping demonstration area) Patentee after: BEIJING QUANTUM HI-TECH PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 102200, No. 11, building 8, Ho Ying Road, Beijing, Changping District Patentee before: Quantum High Technology (Beijing) Research Institute Co., Ltd. |
|
TR01 | Transfer of patent right |